Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $3.29 million. The enterprise value is $10.76 million.
Important Dates
The next estimated earnings date is Tuesday, June 24, 2025, after market close.
| Earnings Date | Jun 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 44.36 million shares outstanding. The number of shares has increased by 541.81% in one year.
| Current Share Class | 44.36M |
| Shares Outstanding | 44.36M |
| Shares Change (YoY) | +541.81% |
| Shares Change (QoQ) | +555.52% |
| Owned by Insiders (%) | 3.01% |
| Owned by Institutions (%) | 0.77% |
| Float | 39.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| Forward PS | n/a |
| PB Ratio | 0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17, with a Debt / Equity ratio of 2.27.
| Current Ratio | 0.17 |
| Quick Ratio | 0.11 |
| Debt / Equity | 2.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.08 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.25% |
| Return on Invested Capital (ROIC) | -55.48% |
| Return on Capital Employed (ROCE) | -130.64% |
| Revenue Per Employee | $385,063 |
| Profits Per Employee | -$11.50M |
| Employee Count | 5 |
| Asset Turnover | 0.04 |
| Inventory Turnover | 3.67 |
Taxes
| Income Tax | -923,613 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.83% in the last 52 weeks. The beta is 3.51, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.51 |
| 52-Week Price Change | -98.83% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 46.78 |
| Average Volume (20 Days) | 20,206,943 |
Short Selling Information
The latest short interest is 1.84 million, so 4.14% of the outstanding shares have been sold short.
| Short Interest | 1.84M |
| Short Previous Month | 6.30M |
| Short % of Shares Out | 4.14% |
| Short % of Float | 4.69% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, Onconetix had revenue of $1.93 million and -$57.49 million in losses. Loss per share was -$683.39.
| Revenue | 1.93M |
| Gross Profit | 911,930 |
| Operating Income | -6.19M |
| Pretax Income | -45.82M |
| Net Income | -57.49M |
| EBITDA | -5.66M |
| EBIT | -6.19M |
| Loss Per Share | -$683.39 |
Full Income StatementBalance Sheet
The company has $1.58 million in cash and $9.05 million in debt, giving a net cash position of -$7.47 million or -$0.17 per share.
| Cash & Cash Equivalents | 1.58M |
| Total Debt | 9.05M |
| Net Cash | -7.47M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 3.99M |
| Book Value Per Share | 9.23 |
| Working Capital | -11.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$7.26 million and capital expenditures -$23,893, giving a free cash flow of -$10.52 million.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | -23,893 |
| Free Cash Flow | -10.52M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
| Gross Margin | 47.37% |
| Operating Margin | -321.38% |
| Pretax Margin | -2,962.74% |
| Profit Margin | n/a |
| EBITDA Margin | -293.89% |
| EBIT Margin | n/a |
| FCF Margin | n/a |